Contact
Please use this form to send email to PR contact of this press release:
ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors
TO: